118 related articles for article (PubMed ID: 31745962)
1. [Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany].
Hupe MC; Hammerer P; Ketz M; Kossack N; Colling C; Merseburger AS
Aktuelle Urol; 2020 Jun; 51(3):275-284. PubMed ID: 31745962
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes.
Hupe MC; Hammerer P; Ketz M; Kossack N; Colling C; Merseburger AS
Front Oncol; 2018; 8():543. PubMed ID: 30538951
[No Abstract] [Full Text] [Related]
3. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.
Shao YJ; Hong JH; Chen CK; Huang CY
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):722-729. PubMed ID: 35662291
[TBL] [Abstract][Full Text] [Related]
4. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
5. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
6. Prescription practice for LH-RH analogs and androgen receptor antagonists in the treatment of advanced prostate cancer in Germany (1993-2003).
Rohde V; Diemer T; Hauck E; Bestmann B; Miller J; Schröder H; Weidner W; Katalinic A
Urol Int; 2006; 77(4):311-6. PubMed ID: 17135780
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer follow-up costs in Germany from 2000 to 2015.
Michaeli T; Michaeli D
J Cancer Surviv; 2022 Feb; 16(1):86-94. PubMed ID: 33646503
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
11. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.
Morgia G; Russo GI; Tubaro A; Bortolus R; Randone D; Gabriele P; Trippa F; Zattoni F; Porena M; Mirone V; Serni S; Del Nero A; Lay G; Ricardi U; Rocco F; Terrone C; Pagliarulo A; Ludovico G; Vespasiani G; Brausi M; Simeone C; Novella G; Carmignani G; Leonardi R; Pinnarò P; De Paula U; Corvò R; Tenaglia R; Siracusano S; Mantini G; Gontero P; Savoca G; Ficarra V;
BJU Int; 2016 Jun; 117(6):867-73. PubMed ID: 26332130
[TBL] [Abstract][Full Text] [Related]
12. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166
[TBL] [Abstract][Full Text] [Related]
13. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
14. The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study.
Shim M; Bang WJ; Oh CY; Lee YS; Jeon SS; Ahn H; Ju YS; Cho JS
J Korean Med Sci; 2020 Feb; 35(4):e47. PubMed ID: 31997617
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
16. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
20. Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.
Carreras MJ; Tomás-Guillén E; Farriols A; Renedo-Miró B; Valdivia C; Vidal J; Saura C; Carles J; Felip E; Gorgas MQ; Tabernero J; Monterde J
Curr Oncol; 2023 Aug; 30(9):7984-8004. PubMed ID: 37754495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]